GR1005153B - Πρωτεινες συντηξεως, παρασκευη τους και χρηση τους. - Google Patents

Πρωτεινες συντηξεως, παρασκευη τους και χρηση τους.

Info

Publication number
GR1005153B
GR1005153B GR900100635A GR900100635A GR1005153B GR 1005153 B GR1005153 B GR 1005153B GR 900100635 A GR900100635 A GR 900100635A GR 900100635 A GR900100635 A GR 900100635A GR 1005153 B GR1005153 B GR 1005153B
Authority
GR
Greece
Prior art keywords
fusion proteins
preparation
manner
oligonucleotide
fusion protein
Prior art date
Application number
GR900100635A
Other languages
English (en)
Other versions
GR900100635A (el
Inventor
Habermann Paul Dr.
Seed Brian Dr.
Stengelin Siefried Dr.
Uhlmann Eugen Dr.
Ulmer Wolfgang Dr.
Original Assignee
The General Hospital Corporation
Sanofi - Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The General Hospital Corporation, Sanofi - Aventis Deutschland GmbH filed Critical The General Hospital Corporation
Publication of GR900100635A publication Critical patent/GR900100635A/el
Publication of GR1005153B publication Critical patent/GR1005153B/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Πρωτεϊνες συντήξεως λαμβάνονται σε μεγάλες αποδόσεις εάν δομηθεί ένα μικτό ολιγονουκλεοτίδιο, το οποίο κωδικεύει το συστατικό έρματος της πρωτεϊνης συντήξεως, το ολιγονουκλεοτίδιο αυτό εισάγεται σε έναν φορέα, κατά τέτοιο τρόπο, ώστε να συνδέεται μεδραστικές ομάδες με μια ρυθμιστική περιοχή και με το δομικό γονίδιο για την επιθυμητή πρωτεϊνη, κατάλληλα κύτταρα-ξενιστές μετασχηματίζονται με τον πλασμιδικό πληθυσμό που λαμβάνεται κατά τον τρόπο αυτό και επιλέγονται οι κλώνοι, που παράγουν υψηλή απόδοση κωδικευμένης πρωτεϊνης συντήξεως.
GR900100635A 1989-08-29 1990-08-27 Πρωτεινες συντηξεως, παρασκευη τους και χρηση τους. GR1005153B (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39987489A 1989-08-29 1989-08-29

Publications (2)

Publication Number Publication Date
GR900100635A GR900100635A (el) 1991-12-30
GR1005153B true GR1005153B (el) 2006-03-13

Family

ID=23581315

Family Applications (1)

Application Number Title Priority Date Filing Date
GR900100635A GR1005153B (el) 1989-08-29 1990-08-27 Πρωτεινες συντηξεως, παρασκευη τους και χρηση τους.

Country Status (20)

Country Link
EP (1) EP0489780B1 (el)
JP (1) JP3043803B2 (el)
KR (1) KR0159786B1 (el)
AT (1) ATE173018T1 (el)
AU (1) AU638277B2 (el)
CA (1) CA2065146C (el)
CY (1) CY2168B1 (el)
DE (1) DE69032743T2 (el)
DK (1) DK0489780T3 (el)
ES (1) ES2124216T3 (el)
FI (1) FI113183B (el)
GR (1) GR1005153B (el)
HK (1) HK1012026A1 (el)
HU (1) HU216069B (el)
IE (1) IE903120A1 (el)
IL (1) IL95495A (el)
NO (1) NO308667B1 (el)
PT (1) PT95111B (el)
WO (1) WO1991003550A1 (el)
ZA (1) ZA906839B (el)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5426036A (en) * 1987-05-05 1995-06-20 Hoechst Aktiengesellschaft Processes for the preparation of foreign proteins in streptomycetes
ATE148710T1 (de) * 1992-12-02 1997-02-15 Hoechst Ag Verfahren zur gewinnung von proinsulin mit korrekt verbundenen cystinbrücken
ATE203998T1 (de) * 1993-04-27 2001-08-15 Hoechst Ag Amorphe monosphärische formen von insulinderivaten
WO1995009914A1 (fr) * 1993-10-05 1995-04-13 Asahi Glass Company Ltd. Vecteur de multiclonage, vecteur d'expression, et production d'une proteine exogene au moyen dudit vecteur d'expression
US6001604A (en) * 1993-12-29 1999-12-14 Bio-Technology General Corp. Refolding of proinsulins without addition of reducing agents
DE4405179A1 (de) * 1994-02-18 1995-08-24 Hoechst Ag Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken
US5683987A (en) * 1994-07-12 1997-11-04 The Board Of Regents Of The University Of Nebraska Therapeutic oligonucleotides targeting the human MDR1 and MRP genes
PT821006E (pt) 1996-07-26 2004-09-30 Aventis Pharma Gmbh Derivados de insulina com ligacao a zinco aumentada
DE19735711C2 (de) 1997-08-18 2001-04-26 Aventis Pharma Gmbh Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken
DE19825447A1 (de) 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
DE19915938A1 (de) 1999-04-09 2000-10-19 Aventis Pharma Gmbh Herstellung von pankreatischer Procarboxypeptidase B, Isoformen und Muteinen davon und ihre Verwendung
DE19930676B4 (de) 1999-07-02 2006-01-19 Sanofi-Aventis Deutschland Gmbh Verfahren zur Stabilisierung von Insulin, Insulinderivaten und/oder deren Vorläufer in komplexen Mischungen bei deren Lagerung in wäßrigen Lösungsmitteln
US7202059B2 (en) 2001-02-20 2007-04-10 Sanofi-Aventis Deutschland Gmbh Fusion proteins capable of being secreted into a fermentation medium
US7638618B2 (en) 2001-02-20 2009-12-29 Sanofi-Aventis Deutschland Gmbh Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest
DE10235168A1 (de) 2002-08-01 2004-02-12 Aventis Pharma Deutschland Gmbh Verfahren zur Reinigung von Preproinsulin
EP1563075A4 (en) * 2002-11-12 2006-09-06 Ckd Bio Corp HUMANINSULIN EXPRESSIVE PLASMIDE AND METHOD FOR THE PRODUCTION OF HUMANINSULIN THEREWITH
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
EP2229407B1 (de) 2008-01-09 2016-11-16 Sanofi-Aventis Deutschland GmbH Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil
DE102008025008A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008025007A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
CN101970476B (zh) 2008-01-09 2014-08-27 塞诺菲-安万特德国有限公司 具有超延迟时效特征的胰岛素衍生物
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
KR101337322B1 (ko) 2009-11-13 2013-12-06 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
ES2534191T3 (es) 2009-11-13 2015-04-20 Sanofi-Aventis Deutschland Gmbh Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
BR112013004756B1 (pt) 2010-08-30 2020-04-28 Sanofi Aventis Deutschland uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2
DK2739646T3 (en) 2011-05-10 2018-02-26 Stefan Hermann COMPREHENSIVE BUFFER SYSTEM FOR RENATURING HUMAN PROINSULIN OR PROINSULIN DERIVATIVES
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
PL2750699T3 (pl) 2011-08-29 2015-12-31 Sanofi Aventis Deutschland Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
JP5858945B2 (ja) 2012-03-15 2016-02-10 アークレイ株式会社 酵素を用いた測定方法
HRP20230470T1 (hr) 2014-12-12 2023-07-21 Sanofi-Aventis Deutschland Gmbh Formulacija fiksnog omjera inzulin glargin/liksisenatid
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US20220154192A1 (en) * 2019-02-19 2022-05-19 The Trustees Of Princeton University System and method for light-regulated oligomerization and phase separation of folded domains and rna granule-associated protein domains for drug- based screening applications

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366246A (en) * 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
US4431739A (en) * 1979-11-05 1984-02-14 Genentech, Inc. Transformant bacterial culture capable of expressing heterologous protein
US4769326A (en) * 1980-02-29 1988-09-06 The Regents Of The University Of California Expression linkers
US4652639A (en) * 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
JPS61264000A (ja) * 1985-03-21 1986-11-21 イミユネツクス　コ−ポレイシヨン 標識ペプチドによるタンパク質の合成
DE3526995A1 (de) * 1985-07-27 1987-02-05 Hoechst Ag Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung

Also Published As

Publication number Publication date
CY2168B1 (en) 2002-08-23
HK1012026A1 (en) 1999-07-23
FI920923A0 (fi) 1992-02-28
DK0489780T3 (da) 1999-07-19
WO1991003550A1 (en) 1991-03-21
AU6287290A (en) 1991-04-08
IL95495A0 (en) 1991-06-30
ATE173018T1 (de) 1998-11-15
ES2124216T3 (es) 1999-02-01
JPH05501799A (ja) 1993-04-08
EP0489780A1 (en) 1992-06-17
HUT60327A (en) 1992-08-28
IL95495A (en) 1996-10-16
NO308667B1 (no) 2000-10-09
CA2065146A1 (en) 1991-03-01
PT95111A (pt) 1991-05-22
FI113183B (fi) 2004-03-15
HU216069B (hu) 1999-04-28
EP0489780B1 (en) 1998-11-04
NO920774L (no) 1992-04-28
JP3043803B2 (ja) 2000-05-22
CA2065146C (en) 2002-07-23
KR0159786B1 (ko) 1998-11-16
EP0489780A4 (en) 1992-08-12
DE69032743T2 (de) 1999-06-17
IE903120A1 (en) 1991-03-13
PT95111B (pt) 1998-10-30
GR900100635A (el) 1991-12-30
AU638277B2 (en) 1993-06-24
NO920774D0 (no) 1992-02-27
DE69032743D1 (de) 1998-12-10
HU9200674D0 (en) 1992-08-28
ZA906839B (en) 1991-06-26

Similar Documents

Publication Publication Date Title
GR1005153B (el) Πρωτεινες συντηξεως, παρασκευη τους και χρηση τους.
ES8802159A1 (es) Un procedimiento de producir un acido desoxirribonucleico (adn)que tiene o contiene una secuencia de base que codificaun polipeptido de factor de necrosis tumoral de humano
ATE88501T1 (de) Rekombinante dns-expressionsvektoren.
IL173399A0 (en) Circular dna molecule with conditional origin of replication which contains nucleic acid of interest and selection marker but does not encode its replication initiation protein, method for preparing the same and use thereof in gene therapy
HUT46061A (en) Dna sequences encoding hirudin-like protein and process for producing such proteins
AU6569386A (en) Eukaryotic fusion proteins, the preparation and use thereof and means for carrying out the process
ES8506347A1 (es) Un metodo para producir un polipeptido de tipo il-2-".
EP0424416A4 (en) Acid-labile subunit (als) of insulin-like-growth factor (igf) binding protein complex
IL135911A0 (en) Dna 19355 polypeptide, a tumor necrosis factor homolog
EP0182448A3 (en) Production of factor viii and related products
AU577810B2 (en) Cloning the gene for rabbit tumor necrosis factor polypeptide
EP0749441A4 (en) EXPRESSION AND PURIFICATION OF CLONE HUMAN ALPHA-F TOPROTEIN
NZ333203A (en) Tumour antigen proteins, genes thereof, and tumour antigen peptides
EP0395706A4 (en) Production of gonorrheal pi proteins and vaccines
EP0546087A4 (el)
GR3027636T3 (en) Anti-feline immunodeficiency virus (fiv) vaccines.
DE69634757D1 (de) Vektor zur expression von n-terminal verlängerten proteinen in hefezellen
JPS6427473A (en) Human pancreas-secreting trypsin inhibitor and production thereof
HUT40164A (en) Process for preparing signal sequency for the transformation of proteins in expression systems
ES8705921A1 (es) Un procedimiento para mejorar la produccion de un polipeptido deseado en un hospedante transformado con una molecula de adn recombinantes.
JPS6474989A (en) Dna to code human lysozyme
MX9707244A (es) Expresion de genes en celulas de mamifero.
JPS6474988A (en) Synthetic gene of cystatin c, corresponding recombinant plasmid and recombinant

Legal Events

Date Code Title Description
PG Patent granted
MA Right expired